Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LN-145 and Pembrolizumab in Advanced Transitional Cell Bladder Cancer
NCT03935347Phase 2Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jun 2019
- Primary completion
- May 2022
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of LN-145 in transitional cell carcinoma (TCC), sponsored by Roswell Park Comprehensive Cancer Center. Planned start Jun 2019; status: withdrawn.
02
Drugs
LN-145
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT03935347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03935347.